Applied Drug Research, Clinical Trials and Regulatory Affairs - Current Issue

Validating computer systems is crucial to meet regulatory requirements, as the lack of proper system integrity can lead to USFDA 483 warning letters. Over the past 5 years, approximately 50 warning letters have been issued for violating computer system requirements, with major comments. Computer System Validation (CSV) is an evaluation process used to test and ensure that the computerized systems used in the pharmaceutical industry are fit for their intended use and meet all regulatory requirements. The major regulations for computer system validation are GAMP and 21 CFR Part 11. In the 1990s, GAMP was established, which mainly focused on the computer systems in industries. Later, 21 CFR Part 11 was issued by the US FDA in 2002. The mainstream and most effective way of computer system validation begins with planning and concludes with result reporting. For a new computer system, its effect on product quality should be checked first; if the system affects the product quality, then system validation is required. If product quality is not affected, then system validation is not required. Various tools can be used for validating different kinds of computer systems. Some of these tools include risk assessment tools, FEMA, testing and validation tools, document management tools, change control management tools, data management tools, and analytics tools.

diagnostics [IVDs] play a critical role in modern healthcare by enabling early disease detection, patient monitoring, and informed treatment decisions. These medical devices are defined and classified based on a risk-based approach, which impacts their entire lifecycle, from development to market access. The global IVD market is growing rapidly, driven by technological advancements and increasing healthcare demands. IVDs are subject to stringent regulations to ensure their safety and effectiveness, with frameworks varying by region. Key guidelines are provided by organizations such as the WHO and regulatory bodies in the US, EU, Japan, Australia, and India. These standards address pre-submission processes, registration requirements, and ongoing compliance to facilitate market entry and maintain patient safety. Market trends reveal a surge in the diversity of IVD products, reflecting their broad applications and technological innovation. From traditional laboratory tests to cutting-edge molecular diagnostics, IVDs cater to a wide range of healthcare needs. However, the integration of IVDs with combination products poses regulatory challenges, requiring careful navigation to ensure compliance. By striking a balance between innovation and regulatory requirements, IVDs continue to transform the healthcare landscape. This review provides stakeholders with a comprehensive understanding of IVD regulation, development, and market dynamics. With a focus on aligning with evolving healthcare priorities and safety standards, IVDs remain pivotal in advancing global health outcomes.

While extending treatment protocols and refining systematic processes within the healthcare industry presents immense promise, artificial intelligence (AI) comes along with multiple benefits. It would arrive at accurate diagnoses of diseases, help generate personalized treatment plans, facilitate corporate interactions in healthcare systems, and benefit both patients and healthcare organizations. With the evolving trends in AI, the healthcare domain expects to see substantial effects in the coming few years, hence calling for strong regulation to ensure the protection of human ethics and practical application. The establishment of common regulatory frameworks will enable responsible usages of AI while accentuating patient rights and privacy concerns. AI is changing how drug approvals are done through positive interventions on both the time and cost aspects.

Whereas traditional drug development takes anywhere from 5.5 years to 14.5 years, AI has shortened this time frame for target discovery to a preclinical candidate to as little as 18 months. Furthermore, AI has reduced development costs by nearly 50%, thus rendering development more efficient while enhancing the accuracy of predictions of the efficacy and safety of drugs. The stepped integration of AI into drug approval processes accelerates innovations by providing cost-effective solutions and enhancing precision that eventually benefits both patients and healthcare organizations.

The Electronic Common Technical Document (eCTD) has streamlined regulatory submissions by offering a standardized format that improves communication and reduces errors. However, challenges such as maintaining compliance, ensuring data security, and managing complex lifecycle updates remain. This paper explores the integration of blockchain technology into eCTD submissions as a solution to these issues. Blockchain’s decentralized and immutable structure enhances data integrity, transparency, and tamper resistance. Smart contracts can automate compliance checks, reduce manual intervention, and improve process efficiency. Additionally, combining blockchain with technologies like artificial intelligence and cloud computing enables real-time data sharing, predictive analytics, and enhanced decision-making. These innovations can lead to faster regulatory reviews and improved stakeholder trust. For successful adoption, blockchain must be harmonized with existing regulatory systems through interoperable platforms and collaborative efforts among regulatory bodies, pharmaceutical companies, and technology providers. This paper highlights how blockchain can transform eCTD submissions by increasing operational efficiency, enhancing data security, and fostering transparent, streamlined regulatory processes.

Due to its ability to track drug interactions and their physiological effects on humans, pharmacovigilance is a vital component of the healthcare system. The ability to monitor and analyze medications for quality as well as identify and halt any unfavorable drug side effects makes pharmacovigilance a crucial component of modern technology. Drug safety data collection and coding, as well as case management reporting and submission, comprise case processing, which is the first step in pharmacovigilance. The Pharmacovigilance Programme of India was established in response to these advancements. India participates in the Uppsala Monitoring Centre system but contributes very little to the database itself. The objective of this research is to conduct a comprehensive analysis of the pharmacovigilance program in India and provide a succinct, current evaluation of the organization, taking into account its background and possible issues. The development of “A Pharmacovigilance Programme of India” mobile application was emphasized by the National Coordination Centre PvPI to India as a means of enhancing public health and encouraging prompt reporting of adverse drug reactions. With more and more cutting-edge veterinary medications entering the market, India needs a veterinary pharmacovigilance system. One of the most significant current responsibilities is demonstrating to the world that thousands of years-old Ayurveda Siddha Unani systems are safe and grounded in science.

Due to its ability to track drug interactions and their physiological effects on humans, pharmacovigilance is a vital component of the healthcare system. The ability to monitor and analyze medications for quality as well as identify and halt any unfavorable drug side effects makes pharmacovigilance a crucial component of modern technology. Drug safety data collection and coding, as well as case management reporting and submission, comprise case processing, which is the first step in pharmacovigilance. The Pharmacovigilance Programme of India was established in response to these advancements. India participates in the Uppsala Monitoring Centre system but contributes very little to the database itself. The objective of this research is to conduct a comprehensive analysis of the pharmacovigilance program in India and provide a succinct, current evaluation of the organization, taking into account its background and possible issues. The development of “A Pharmacovigilance Programme of India” mobile application was emphasized by the National Coordination Centre PvPI to India as a means of enhancing public health and encouraging prompt reporting of adverse drug reactions. With more and more cutting-edge veterinary medications entering the market, India needs a veterinary pharmacovigilance system. One of the most significant current responsibilities is demonstrating to the world that thousands of years-old Ayurveda Siddha Unani systems are safe and grounded in science.

Brain-computer interface (BCI) technology has emerged as a groundbreaking innovation with transformative potential in medical devices. BCIs are analyzed for their ability to diagnose, treat, and manage neurological disorders, such as Parkinson's disease, ALS, and stroke.

The study explores the integration of BCI technology into medical devices and examines the challenges and opportunities regulatory authorities face in overseeing this rapidly evolving field.

The study employs a comprehensive literature review with the help of databases like Google Scholar, and PubMed, analyzing case studies and regulatory requirements.

BCI technology enables direct communication between the human brain and external devices, allowing for the control of computers or prosthetic limbs. Additionally, software tools facilitate the analysis of recorded brain signals, aided by advancements in Artificial Intelligence (AI), including Machine Learning (ML) and Deep Learning (DL), for automatic classification of EEG signals. However, the rapid advancement leads to high costs and complexity of BCI systems which can limit their accessibility and scalability, posing a barrier. Moreover, the development of standardized protocols and guidelines for BCI implementation is essential to maintain consistency and reliability across applications.

The ethical considerations surrounding BCI technology are vital and emphasize the need for government regulations to ensure its safe and effective integration into healthcare. BCI's potential for responsible innovation in patient-centric care is advocated, propelling medical technology into a new era of seamless integration and improved patient outcomes.

Contract Research Organizations are bodies that offer research and development services on a contract basis to the pharmaceutical, biotechnology, medical device, and other industries. These organizations offer a wide range of services to support the drug discovery, development, and commercialization process. Initially, CROs begin with clinical trial management facilities and assisting sponsors with clinical study design, whereas laboratory CROs provide drug discovery, manufacturing, and bioanalytical services, including site feasibility. Their services mainly cover pharmaceutical and biotechnology industry based work such as drug development, pharmaceutical product development, clinical and preclinical trials, analytical method developments, pharmacovigilance, medical writing, etc. India presents itself as a wonderful platform for CROs attributing to its huge population, varied disease conditions, accessible human resources, large number of hospitals and low treatment cost. In the clinical trial process, CROs are engaged by the sponsor to accomplish a number of duties, taking into account various administrative and technical responsibilities on behalf of the sponsor. The current manuscript highlights the globalization of clinical trials, the concept of CRO, roles and responsibilities, functions of CROs, regulatory infrastructure of CRO, criteria for selection of suitable CRO, Indian CRO market and impact of COVID-19 pandemic on it.

Blockchain technology is a decentralized, peer-to-peer network-based public, encrypted, and immutable digital federated ledger system with various applications in the digital economy. This paper examines how blockchain technology can strengthen intellectual property rights (IPR) in the digital age and the potential challenges and risks associated with this use. The paper analyses the advantages and disadvantages of blockchain technology for confirming and protecting IPR, such as transparency, security, efficiency, and scalability, as well as issues such as legal uncertainty, interoperability, and governance. The paper also explores the implications of blockchain technology for different types of IPR, such as patents, and copyrights, and how it can facilitate innovation, licensing, and enforcement. The paper concludes by providing recommendations for improving the legal and regulatory framework for IPR management using blockchain technology and identifying some areas for further research.